CX-516

CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and had been undergoing development by a collaboration between Cortex, Shire, and Servier. It was studied as a potential treatment for Alzheimer's disease under the brand name Ampalex, and was also being examined as a treatment for ADHD.

CX-516

Clinical data
Trade names	Ampalex
Pharmacokinetic data
Elimination half-life	45 minutes
Identifiers
IUPAC name 6-(Piperidin-1-ylcarbonyl)quinoxaline
CAS Number	154235-83-3 Y
PubChem CID	148184
IUPHAR/BPS	4165
ChemSpider	130635 Y
UNII	Z5QU38B4V9
KEGG	C13675 Y
ChEMBL	ChEMBL136800 Y
CompTox Dashboard (EPA)	DTXSID70165574
ECHA InfoCard	100.237.047
Chemical and physical data
Formula	C14H15N3O
Molar mass	241.294 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(c2cc1nccnc1cc2)N3CCCCC3
InChI InChI=1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2 Y Key:ANDGGVOPIJEHOF-UHFFFAOYSA-N Y
(verify)

CX-516 was the first ampakine compound developed by Cortex and while it showed good in vitro activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. However, CX-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such as farampator and CX-717 are compared to.

See also

• AMPA receptor positive allosteric modulator

References

• Danysz W (July 2002). "CX-516 Cortex pharmaceuticals". Current Opinion in Investigational Drugs. 3 (7): 1081–8. PMID 12186271.